ArriVent BioPharma, Inc.

Contributing Author

Recent Articles by ArriVent BioPharma, Inc.

Oct-25	ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 AVBP GlobeNewswire
Oct-23	ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026 AVBP +9.38% AVBP -26.86% GlobeNewswire
Oct-19	ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer AVBP +7.68% GlobeNewswire
Oct-12	ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002 AVBP GlobeNewswire
Oct-06	ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC AVBP -46.98% GlobeNewswire
Aug-12	ArriVent BioPharma Reports Second Quarter 2026 Financial Results AVBP GlobeNewswire
May-11	ArriVent BioPharma Reports First Quarter 2026 Financial Results AVBP GlobeNewswire
May-07	ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers AVBP GlobeNewswire
Mar-17	ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting AVBP GlobeNewswire
Mar-05	ArriVent BioPharma Reports Full Year 2025 Financial Results AVBP AVBP -7.21% GlobeNewswire
Dec-22	ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer AVBP GlobeNewswire
Nov-10	ArriVent BioPharma Reports Third Quarter 2025 Financial Results AVBP GlobeNewswire
Sep-22	ArriVent Appoints Brent S. Rice as Chief Commercial Officer AVBP +5.50% GlobeNewswire
Sep-09	Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer AVBP GlobeNewswire
Aug-11	ArriVent BioPharma Reports Second Quarter 2025 Financial Results AVBP GlobeNewswire
Jul-21	ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 AVBP GlobeNewswire
Jul-01	ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants AVBP GlobeNewswire
Jul-01	ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants AVBP GlobeNewswire
Jun-23	ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study AVBP -9.60% GlobeNewswire
Jun-20	ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC AVBP GlobeNewswire
May-12	ArriVent BioPharma Reports First Quarter 2025 Financial Results AVBP GlobeNewswire

ArriVent BioPharma, Inc.

Recent Articles by ArriVent BioPharma, Inc.

Upgrade your Finviz experience